Home › Calculator › IKT Dividend Calculator 2026
IKT Dividend DRIP Calculator 2026
98.04% YieldHealthcareInhibikase Therapeutics, Inc. · NASDAQ
Price: $2.04 · Annual div: $2.00/share · Frequency: quarterly · Payout ratio: 50% · Ex-div: TBD
Calculator settings
Portfolio growth: DRIP vs No DRIP
Annual dividend income growth
💡 What-if scenarios
Click to apply scenario to the calculator
🎯 When IKT pays your bills
Year your monthly dividend income covers each expense (based on current settings)
Share your IKT snowball 📈
$10,000 in IKT → $698055102117.38M in 10 years · $58,113,372,142,998,500.00/month
About Inhibikase Therapeutics, Inc. (IKT) — Dividend Analysis 2026
Inhibikase Therapeutics, Inc. operates as a clinical-stage pharmaceutical company that develops therapeutics to modify the course of cardiopulmonary diseases, with a primary focus on pulmonary arterial hypertension (PAH), a progressive, life-threatening disease characterized by pulmonary vascular remodeling and elevated pulmonary vascular resistance. It offers IKT-001, a novel oral prodrug of imatinib mesylate designed for the treatment of pulmonary arterial hypertension (PAH) was designed to improve areas of the molecule that might play a role in the gastrointestinal side effects associated with imatinib, while maintaining systemic exposure and efficacy through oral administration. The company has completed non-human primate safety studies and a bioequivalence clinical study in healthy volunteers, establishing dose equivalence with imatinib. IKT-001 is currently being evaluated in a global, adaptive Phase 3 clinical trial (IMPROVE-PAH), with endpoints including pulmonary vascular resistance and 6-minute walk distance. Inhibikase Therapeutics, Inc. entered into a collaborative research and development agreement with Sphaera Pharma Pte. Ltd., which was subsequently assigned to Pivot Holding LLC, for prodrug technology development and maintains an exclusive license for IKT-001. The company was founded in 2008 and is headquartered in Wilmington, Delaware.
Compare IKT with similar stocks
This calculation uses the DividendFlow Engine v6.0. Data is verified daily against SEC filings and FMP real-time feeds to ensure projection accuracy.
Get Your Full IKT DRIP Report by Email
We'll send you a full breakdown of your projections, DRIP tips, and how to enable dividend reinvestment with your broker.
Free forever. No spam. Unsubscribe anytime. · Privacy Policy
Ready to invest? Open IKT position with:
🌍 IKT Yield by Country & Account Type
Real after-tax yield depends on where you live and how you hold IKT.
| Account/Country | Tax Rate | After-tax Yield | Real Yield | $10K Annual Income |
|---|---|---|---|---|
| 🇺🇸 Roth IRA / 401k | 0% | 98.04% | 95.24% | $9,804 / yr |
| 🇺🇸 US Taxable (15%) ✓ | 15% | 83.33% | 80.53% | $8,333 / yr |
| 🇺🇸 US Taxable (20%) | 20% | 78.43% | 75.63% | $7,843 / yr |
| 🇬🇧 UK ISA | 0% | 98.04% | 95.24% | $9,804 / yr |
| 🇬🇧 UK Taxable | 8.75% | 89.46% | 86.66% | $8,946 / yr |
| 🇨🇦 TFSA | 0% | 98.04% | 95.24% | $9,804 / yr |
| 🇨🇦 CA Taxable | 25% | 73.53% | 70.73% | $7,353 / yr |
| 🇦🇺 Super (pension) | 15% | 83.33% | 80.53% | $8,333 / yr |
| 🇦🇺 AU Taxable | 30% | 68.63% | 65.83% | $6,863 / yr |
| 🇩🇪 DE Taxable | 26.375% | 72.18% | 69.38% | $7,218 / yr |
| 🇫🇷 FR Taxable | 30% | 68.63% | 65.83% | $6,863 / yr |
Real yield = after-tax yield minus US CPI of 2.8%. 12-month CPI (US BLS via FMP economic-indicators). Click any row to select. US withholding tax (30%, reducible by treaty) applies to non-US residents holding US stocks in taxable accounts.
🎯 IKT Income Goal & Break-Even
12-month CPI (US BLS via FMP economic-indicators).
Based on current dividend of $2.00/share/yr · 🇺🇸 US Taxable (15%) · static projection (no growth assumed).
📅 IKT Dividend Payment Schedule
IKT pays quarterly — 4 times per year. Next ex-div: TBD.
📊 IKT vs Healthcare Benchmarks
How IKT compares to typical Healthcare averages.
Benchmarks: S&P 500 sector averages (2024–2026). Sources: Morningstar, Bloomberg, NAREIT. 5Y CAGR for IKT sourced from FMP /financial-growth endpoint — real data, not estimates.
🏛️ IKT Insider Activity
When executives buy their own stock, it's a signal they believe in the dividend's sustainability.
| Insider | Title | Type | Date | Shares | Price | Total Value |
|---|---|---|---|---|---|---|
| A-Award | 2026-06-26 | 155,000 | $1.91 | $296.1K | ||
| A-Award | 2026-06-26 | 155,000 | $1.91 | $296.1K | ||
| A-Award | 2026-06-26 | 155,000 | $1.91 | $296.1K | ||
| A-Award | 2026-06-26 | 155,000 | $1.91 | $296.1K | ||
| A-Award | 2026-06-26 | 155,000 | $1.91 | $296.1K | ||
| A-Award | 2026-06-26 | 155,000 | $1.91 | $296.1K | ||
| D-Return | 2026-02-21 | 255,299 | — | — | ||
| D-Return | 2026-02-21 | 338,282 | — | — | ||
| D-Return | 2026-02-21 | 19,089 | — | — | ||
| A-Award | 2026-01-05 | 4,982,706 | $2.01 | $10.02M |
Insider transactions sourced from SEC Form 4 filings via Financial Modeling Prep. See disclaimer.
Analyst Price Target
Wall Street consensusAnalyst consensus price target via FMP. Not a guarantee of future performance. Past analyst accuracy varies.
Financial Health Scores
Altman Z-Score predicts bankruptcy risk. Piotroski F-Score measures financial strength across 9 criteria. High scores → lower dividend cut risk. Data via FMP financial statements.
Dividend yields, payout ratios, and financial metrics are sourced from Financial Modeling Prep (FMP) and cross-referenced with SEC EDGAR filings. Data is cached and updated every 24 hours via our nightly refresh. DRIP projections are forward-looking estimates, not guarantees.
Educational purposes only. Not financial advice. DividendFlow is not a registered investment advisor. Projections generated by the IKT dividend calculator are estimates based on historical data and user inputs. Actual future returns, stock prices, and dividend payments will vary. Dividends can be cut or suspended at any time. All investments carry risk, including the loss of principal. Please consult a qualified financial professional before making any investment decisions. Full disclaimer →
Inhibikase Therapeutics, Inc. (IKT) is currently trading at $2.04, 95% below its 52-week high. The current dividend yield is 98.04% based on an annual payout of $2.00 per share.
IKT (Inhibikase Therapeutics, Inc.) — 98.04% Dividend Yield Analysis
Inhibikase Therapeutics, Inc. (IKT) is a healthcare stock currently trading at $2.04 with a dividend yield of 98.04%. The company pays an annual dividend of $2.00 per share. The payout ratio of 50% suggests the dividend is well-covered by earnings.
- Above-average yield (98.04%) may signal elevated risk — verify sustainability.
Auto-generated from live market data. For educational purposes only — not financial advice.
Latest IKT News
LiveNews aggregated from public sources via Finnhub & RSS. For informational purposes only.